Where this Hodgkin lymphoma information comes from
On this page are the major sources of information that we use to put together this section on Hodgkin lymphoma.
All our information is checked by cancer specialists and surgeons who specialise in treating cancer. The names of our specialist reviewers are at the end of this list. We also try to find patients to review all our sections. If you have had Hodgkin lymphoma (Hodgkin's disease), live in the UK and would like to become a patient reviewer, you can write to us by clicking on contact us.
Cancer Research UK
US National Cancer Institute
Information on the treatment of Hodgkin lymphoma
Principles and practice of oncology (9th edition)
De Vita, V.T., Hellman, S. and Rosenberg S.A.
Lippincott, Wiliams and Wilkins, 2011
Cancer and its management (6th edition)
Tobias J and Hochhauser D
Blackwell Publishing Ltd, 2010
Essential Haematology (6th Edition)
Hoffbrand V and Moss P
Improving outcomes in haematological cancer.
The national Institute for Health and Care Excellence (NICE), 2003
Link to the NICE haematological cancer guidance
Referral for suspected cancer. A clinical practice guideline.
The National Institute for Health and Care Excellence (NICE), June 2015
Link to the referral guidelines on the NICE website
Hodgkin's lymphoma map of medicine
Link to the Hodgkin's lymphoma map of medicine
Guidelines for the first line management of classical Hodgkin lymphoma.
British Committee for Standards in Haematology (BCSH), Feb 2014
Link to the BCSH guidelines
Hodgkin's lymphoma in adults. Townsend W, Linch D, The Lancet, 1 September 2012; 380: 836-47.
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Eichenauer D, Engert A et al: Annals of Oncology (2014).
Novel therapy for Hodgkin lymphoma: Batlevi CL, Younes A: American Society of Hameatology (2013).
Developments in the management of Hodgkin’s lymphoma. Lowry L, Hoskin P, Linch D. Comment in The Lancet. 19 February, 2010.
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Ru T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M. Blood: 1 January 2008; Vol 111, No 1.
A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Koh E, Huan Tran T, Heydarian M, Rainer K, Tsang R, Brenner D, Pintilie M, Xu T, Chung J, Paul N, Hodgson D. Radiation Oncology 2007, 2:13.
Management of Hodgkin Lymphoma. Ansell, S.M, and Armitage, J. O. Mayo Clinic Proceedings (2006) 81; (3); 419-26.
Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Franklin J. G, Paus M. D, Pluetschow A, Specht L. Cochrane Database of Systematic Reviews 2005, Issue 4.
Hodgkin's Lymphoma. Yung, L and Linch, D. The Lancet, March 2003; 361; (9361); 943-951
Dr P Mahendra MD FRCP FRCPath
Dee McLean - McDee Art, Medical Illustration
Question about cancer? Contact our information nurse team